Another positive step towards cure / mitigation of Alzheimer's disease.
AC Immune announced today in a company release that one of the primary objectives of the Phase 2 trial with partner Genentech (Roche Group) has been met.
AC Immune's stock is up 70% as a result.
Announcement from AC Immune:
https://ir.acimmune.com/news-releases/news-release-details/ac-immune-announces-first-positive-cognitive-results-tau
$IMR (+3.5%)
$RHO (+1.22%)
